Several medicines interact with this treatment. Thiazides reduce the renal elimination of lithium and increase the risk of toxicity: the combination is not advised. They also decrease the elimination of uric acid, with which they compete on the same transporter, which explains the hyperuricaemia. The hypokalaemia they cause increases the heart’s sensitivity to digitalis and can promote serious arrhythmias. NSAIDs and salicylates such as aspirin reduce the diuretic effect and increase the risk of acute kidney failure. Because of spironolactone, combining an ACE inhibitor, an ARB or a potassium supplement raises the risk of hyperkalaemia.
Monitoring relies on regular blood tests. They check blood sodium, blood potassium, blood uric acid, blood calcium and kidney function, because the treatment shifts these parameters. Blood potassium requires particular attention: the thiazide tends to lower it, spironolactone to raise it, and other medicines such as beta-blockers, ACE inhibitors and ARBs can worsen hyperkalaemia. Finally, thiazides are contraindicated in cases of anuria, the absence of urine output, and of allergy to sulphonamides, because they contain a sulphonamide group.